Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ-REUMA: Shingrix in inflammatory rheumatic diseases
2023-506230-71-01Phase 4Authorised
- Sponsor
- Skåne University Hospital
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Skåne University Hospital. Planned start Nov 2023; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2023-506230-71-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506230-71-01.